BTZ is an FDA-approved, first-line chemotherapeutic agent indicated for patients with newly diagnosed and relapsed multiple myeloma, which acts as a selective, reversible boronic acid dipeptidase inhibitor of the 20S proteasome protein complex in multiple myeloma secretory cells [10]. This evidence concerns the gene CASC3 and plasma cell myeloma.